Navigation Links
Effective cancer immune therapy through order in the blood vessels
Date:4/21/2008

Immune therapies are considered very promising in cancer medicine: Tumor-fighting immune cells are supposed to invade tumor tissue and eliminate cancer cells right there. Although this works well in the test tube, clinical application often fails because immune cells are unable to get into the tumor tissue from the bloodstream in sufficient numbers.

This is due, among other things, to the chaotic tumor vasculature: To get supplied with nutrients, a tumor stimulates the formation of new vessels. However, the architecture of these newly formed blood vessels differs from the normal one; they are poorly organized and regarded as immature. Therefore, in many tumors, immune cells have difficulty entering the cancer tissue. Studies show, however, that patients survive longer when immune cells are able to invade the tumor.

In an article published in Nature, scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and Heidelberg University Hospitals, jointly with Australian researchers, have now described a key molecule that is responsible for the immature state of the tumor vasculature. In mice suffering from cancer whose gene encoding the Rgs5 signal protein is switched off, the investigators observed a normalization of blood vessels in the tumor. Tumor-specifically activated immune cells that were transplanted into these animals were found to colonize the cancer tissue in large numbers. In contrast, in mice with normal Rgs5 status, there is no significant invasion of immune cells into the tumor.

Survival rates clearly showed the success of the immune therapy: While some of the Rgs5-deficient animals were still alive after 48 weeks into the investigation, all animals with normal Rgs5 formation had died from cancer after 35 weeks at the latest. Vaccination with tumor-specific proteins also resulted in improved survival times of Rgs5-deficient mice, while it showed no effect in control animals.

We were surprised that a gene that apparently affects vascular structure has such a strong influence on the success of immune therapies. Rgs5 is, thus, a completely new, promising target structure for clinical tumor therapy, says DKFZs Professor Gnter Hmmerling, one of the scientists leading the study. But we dont necessarily have to knock out Rgs5 to improve the success of immune therapies. Available therapeutics that normalize tumor vasculature should also increase the invasion of immune cells into tumor tissue.

Juliana Hamzah, Manfred Jugold, Fabian Kiessling, Paul Rigby, Mitali Manzur, Hugo H. Marti, Tamer Rabie, Sylvia Kaden, Hermann-Josef Grne, Gnter J. Hmmerling, Bernd Arnold and Ruth Ganss: Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, DOI: 10.1038/nature06868

The task of the Deutsches Krebsforschungszentrum in Heidelberg (German Cancer Research Center, DKFZ) is to systematically investigate the mechanisms of cancer development and to identify cancer risk factors. The results of this basic research are expected to lead to new approaches in the prevention, diagnosis and treatment of cancer. The Center is financed to 90 percent by the Federal Ministry of Education and Research and to 10 percent by the State of Baden-Wuerttemberg. It is a member of the Helmholtz Association of National Research Centers (Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V.).


'/>"/>
Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Gypsy moth management made more efficient, cost-effective
2. Poll Shows Strong Doubts About Effectiveness of Federal Employment Verification System
3. HR Initiative Endorses Bill to Create an Effective, Mandatory Federal Employment Verification System
4. Effective ADHD treatment found for children with fragile X syndrome
5. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
6. Safe and effective therapy discovered for patients with protein-losing enteropathy
7. Tamiflu effective for treatment and prevention of influenza in children 1 year and older
8. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
9. Quantitative PET imaging finds early determination of effectiveness of cancer treatment
10. New hope for horse lovers as effective control for killer ragwort is proposed
11. Trial seeks genetic fingerprint for predicting drug effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):
(Date:3/30/2017)... PARK, CA (PRWEB) , ... March 30, 2017 ... ... cell (CTC) capture systems, will present four posters at the American Association ... presented at AACR demonstrate the ability of Vortex’s technology to rapidly collect highly ...
(Date:3/30/2017)... DUBLIN , March 30, 2017  Jazz Pharmaceuticals ... it has entered into license agreements with Nippon Shinyaku, ... Vyxeos ™ (cytarabine and daunorubicin liposome injection), or ... Under the terms of the agreements, Nippon Shinyaku will ... Vyxeos in Japan in return ...
(Date:3/30/2017)... Personal Genome Diagnostics Inc. (PGDx) today announced that ... for Cancer Research (AACR) Annual Meeting 2017, being held April ... company also announced that five scientists associated with PGDx—two co-founders ... Annual AACR Team Science Award. ... Doug Ward , CEO of ...
(Date:3/29/2017)... Washington, PA (PRWEB) , ... March 29, 2017 ... ... largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases ... healthcare professionals, have partnered to deliver exclusive content to ReachMD learners. , ...
Breaking Biology Technology: